Biotyscience Inc
Tel 400-669-8850
E-mail info@biotyscience.com
QQ 499854788
82458988
Cat No | ADMD-077 |
Conjugate | |
Type | 重组蛋白 |
Source | HEK293 |
Tag | Myc,His |
Size | 1mg |
Application | Immunology |
Format | Liquid |
Purity | >95 %, SDS-PAGE |
Concentration | Please refer to the vial lable for the specific concentration. |
Buffer | Supplied in PBS |
Species | Human |
Storage | Store at -20 degree. Avoid repeated freeze/thaw cycles. |
Synonyms | ACT35, CD134, OX40, OX40L receptor, TNFRSF4, TXGP1L |
Purification | Protein A/G |
Note | For research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. |
MolecularWeight | 22.5 kDa |
Description | |
Background | CD134 (OX40, TNFRSF4) is a member of the TNFR-superfamily of receptors. Recent evidence indicates that OX40-OX40L coupling is critical for cell survival and proliferation. While OX40 is expressed predominantly on T-lymphocytes early after antigen activation, OX40L is expressed on activated antigen presenting cells and endothelial cells within acute inflammatory environments. The tumour necrosis factor receptor OX40 (CD134) is activated by its cognate ligand OX40L (CD134L, CD252) and functions as a T cell co-stimulatory molecule. OX40 is expressed on activated T cells, and in the mouse at rest on regulatory T cells (Treg). CD134 can interact with TRAF2, TRAF3, and TRAF5. OX40 is an immune checkpoint in cancer and its presence in cancer is a good prognosis, making it a highly relevant target for the development of new immunotherapies. |